TR-701 FA + Linezolid
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Skin and Subcutaneous Tissue Bacterial Infections
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Trial Timeline
Aug 15, 2010 → Sep 30, 2011
NCT ID
NCT01170221About TR-701 FA + Linezolid
TR-701 FA + Linezolid is a phase 3 stage product being developed by Merck for Skin and Subcutaneous Tissue Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01170221. Target conditions include Skin and Subcutaneous Tissue Bacterial Infections.
What happened to similar drugs?
16 of 20 similar drugs in Skin and Subcutaneous Tissue Bacterial Infections were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01421511 | Phase 3 | Completed |
| NCT01170221 | Phase 3 | Completed |
Competing Products
20 competing products in Skin and Subcutaneous Tissue Bacterial Infections